Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
Background: Lung cancer is a major public health issue and an enormous burden on society in China. Most lung cancers occur in elderly patients with non-small cell lung cancer (NSCLC), and many factors limit their treatment options. Chemotherapy-free therapy can avoid psychological fear, treatment pa...
Main Authors: | Wenbo Qi, Dayong Xi, Yuping Bai, Le Liu, Yanling Ma, Zhenyu Yin, Hao Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1026135/full |
Similar Items
-
Efficacy of Combination of Camrelizumab with Anlotinib as Third-line Therapy for Patients with Advanced Non-small Cell Lung Cancer
by: ZHANG Xiaojuan, et al.
Published: (2023-06-01) -
Effect of anlotinib combined with
camrelizumab on clinical efficacy and short-term prognosis in male patients with
advanced gastric cancer
by: Tianliang Xu, et al.
Published: (2023-05-01) -
Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review
by: Yunpeng Wang, et al.
Published: (2022-10-01) -
TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
by: Chunguang Guo, et al.
Published: (2022-03-01) -
The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
by: Zhimin Zeng, et al.
Published: (2022-10-01)